The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure
10.1136/ejhpharm-2022-003297
May 16, 2022
EAHP Statement 1: Introductory Statements and Governance
A qualitative evaluation of weekly reflective practice sessions for the intensive care unit pharmacy team during the COVID-19 pandemic
10.1136/ejhpharm-2021-003164
April 15, 2022
Impact of a pharmaceutical intervention on influenza vaccination in patients receiving treatment with biological medicines
10.1136/ejhpharm-2021-003175
March 31, 2022
Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD
10.1136/ejhpharm-2021-003015
February 25, 2022
Antifungal drug resistance: an update
10.1136/ejhpharm-2020-002604
February 21, 2022
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
10.1136/ejhpharm-2021-002998
January 20, 2022
Use of simulation for education in hospital pharmaceutical technologies: a systematic review
10.1136/ejhpharm-2021-003034
December 23, 2021
Toward a better understanding about real-world evidence
10.1136/ejhpharm-2021-003081
December 2, 2021
Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
10.1136/ejhpharm-2021-002955
November 22, 2021
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
10.1136/ejhpharm-2021-002798
October 7, 2021